A 52-year-old patient with a BMI of 38 kg/m² and hypertriglyceridemia presents after 14 months on semaglutide (Wegovy) 2.4 mg weekly. Body weight has decreased 11% from baseline — clinically meaningful, but below the 15% threshold her endocrinologist set for reassessing bariatric consultation. The conversation about switching to tirzepatide (Zepbound) begins. Until January 2025, that conversation relied entirely on cross-trial extrapolation between separate pivotal programs with different populations and designs. It no longer has to.
Pharmacological Mechanism: GLP-1 Mono-Agonism vs Dual GIP/GLP-1 Agonism
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist engineered with a C18 fatty diacid chain that extends plasma half-life to approximately 165–184 hours, enabling once-weekly dosing. At the hypothalamic level, GLP-1 receptor activation reduces food intake via arcuate nucleus signaling, increases satiety, and slows gastric emptying. Peripherally, GLP-1 receptor agonism augments glucose-dependent insulin secretion and suppresses glucagon release in a glucose-dependent manner.
Tirzepatide co-activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors — a pharmacological classification termed dual incretin agonism, sometimes called a twincretin. GIP receptor activation in adipose tissue may augment lipid oxidation and modulate adiponectin release; preclinical data from murine models also suggest central GIP receptor activity may attenuate GLP-1-associated nausea signaling. The mechanistic contributions of GIP co-agonism at approved human clinical doses remain under active investigation, but the functional outcome — greater weight reduction than GLP-1 mono-agonism — is now confirmed in a prospective randomized trial.
SURMOUNT-5: The First Prospective Head-to-Head Comparison for Weight Loss
The SURMOUNT-5 trial (NCT05822791) represents the highest-quality direct comparison currently available between semaglutide and tirzepatide for obesity pharmacotherapy. Published in the New England Journal of Medicine in January 2025, the trial enrolled 751 adults with obesity (BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity) without type 2 diabetes at enrollment. Participants were randomized to tirzepatide (flexible dosing at 10 mg or 15 mg weekly per tolerability) or semaglutide 2.4 mg weekly — the approved obesity dose for each agent. Trial duration was 72 weeks.
Primary endpoint results at 72 weeks:
- Tirzepatide: −20.2% mean body weight reduction from baseline
- Semaglutide 2.4 mg: −13.7% mean body weight reduction from baseline
- Treatment difference: −6.5 percentage points (95% CI: −7.9 to −5.1; p<0.001)
The clinical magnitude of the difference can be anchored concretely: for a 120 kg participant, a 6.5-percentage-point efficacy advantage translates to approximately 7.8 kg of additional weight reduction at the population-mean level. For a 150 kg participant, that figure approaches 9.75 kg. The proportion of participants achieving ≥25% body weight loss was 32.3% with tirzepatide versus 15.6% with semaglutide — roughly double the rate of deep response. At the ≥15% threshold, the gap was also substantial: approximately 62% (tirzepatide) versus 42% (semaglutide).
Waist circumference and systolic blood pressure were among the secondary endpoints: tirzepatide showed mean systolic BP reductions of approximately −7.2 mmHg versus −5.3 mmHg for semaglutide — directionally consistent with the greater weight reduction, though not a primary outcome analysis.
Pivotal Trial Benchmarks: STEP and SURMOUNT Programs in Context
Prior to SURMOUNT-5, clinicians evaluating agent selection relied on indirect comparisons between the STEP program (semaglutide) and the SURMOUNT program (tirzepatide). These placebo-controlled trials are not substitutes for a head-to-head design, but they establish the efficacy range for each agent and provide population-level context.
STEP 1 (NCT03548935): Semaglutide 2.4 mg versus placebo in 1,961 adults with obesity without type 2 diabetes over 68 weeks. Mean body weight reduction: −14.9% (semaglutide) versus −2.4% (placebo; p<0.001). Approximately 86.4% of semaglutide participants achieved ≥5% weight loss. (Wilding et al., NEJM 2021; PMID: 33567185.)
SURMOUNT-1 (NCT04184622): Tirzepatide at 5, 10, and 15 mg versus placebo in 2,539 adults with obesity without type 2 diabetes over 72 weeks. Mean weight reductions at 72 weeks: −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% for placebo (all doses p<0.001). The 15 mg dose produced ≥20% weight loss in 56.8% of participants. (Jastreboff et al., NEJM 2022; PMID: 35658024.)
Key indirect comparison limitations: STEP 1 ran 68 weeks versus SURMOUNT-1's 72 weeks; baseline BMI distributions, comorbidity burden, and geographic enrollment differed between programs. Observed efficacy differences across these trials reflect both pharmacological differences and trial design variation. SURMOUNT-5 eliminates those confounders — which is why the 6.5-percentage-point difference it reports should be considered the more reliable estimate of the true efficacy gap.
Metabolic Marker Outcomes: Glycemic Control, Lipids, and Blood Pressure
Body weight is a primary endpoint and a surrogate for downstream cardiometabolic risk reduction. Pivotal trial data across both programs also capture glycemic, lipid, and hemodynamic outcomes that matter to clinicians managing patients with metabolic syndrome, type 2 diabetes, or cardiovascular risk factors.
HbA1c reduction in type 2 diabetes: SURPASS-2 (NCT03987919) compared tirzepatide (5, 10, 15 mg) to semaglutide 1.0 mg — the standard T2D dose, not the 2.4 mg obesity dose — in 1,879 adults with type 2 diabetes over 40 weeks. HbA1c reductions: −2.01% (tirzepatide 5 mg), −2.24% (10 mg), −2.30% (15 mg) versus −1.86% (semaglutide 1.0 mg; p<0.001 for 10 mg and 15 mg vs semaglutide). Weight loss also favored tirzepatide in SURPASS-2 across all dose comparisons. The critical caveat: semaglutide 1.0 mg is not equivalent to 2.4 mg. A direct comparison of tirzepatide against semaglutide 2.4 mg on glycemic endpoints in a powered T2D cohort does not yet exist in published literature.
Triglycerides and lipid profiles: SURMOUNT-1 reported mean triglyceride reductions of 24.5–27.4% across tirzepatide dose groups at 72 weeks. STEP 1 reported triglyceride reductions of approximately 24% with semaglutide 2.4 mg. Both agents also improved HDL-C and modestly reduced LDL-C. SURMOUNT-5 did not identify a statistically significant between-group lipid superiority for either agent, suggesting lipid effects are broadly comparable at their respective approved obesity doses.
Hepatic steatosis: Post-hoc analyses from SURMOUNT-1 and imaging substudies from the STEP program have both shown reductions in hepatic fat fraction. Neither SURMOUNT-5 nor a dedicated head-to-head hepatic outcomes trial has yet established differential superiority. Separate dedicated NASH/MASH trials are ongoing for both compounds.
Safety and Tolerability: Comparative Adverse-Event Profiles
GI adverse events are the dominant tolerability concern for both GLP-1 mono-agonists and dual incretin agonists. SURMOUNT-5 provides the most direct available comparison, and its findings do not support a clinically significant safety advantage for either agent at population level.
GI adverse events (nausea, vomiting, diarrhea, constipation, any severity) were reported in approximately 77% of tirzepatide participants and 72% of semaglutide participants. The 5-percentage-point numerical excess for tirzepatide did not translate to meaningfully different discontinuation behavior: 8.1% of tirzepatide participants discontinued due to adverse events versus 6.6% for semaglutide — a difference that did not reach statistical significance. Overall trial attrition was 14.2% (tirzepatide) and 13.0% (semaglutide), reflecting broadly comparable dropout curves.
Gallbladder-related events — cholelithiasis and cholecystitis — occurred at similar rates in both arms, consistent with the established association between rapid weight loss and gallstone formation independent of mechanism. FDA labeling for both agents includes warnings regarding cholelithiasis, pancreatitis risk, and, in patients with relevant personal or family history, medullary thyroid carcinoma (based on rodent carcinogenicity studies; human relevance is not established but warrants disclosure).
Resting heart rate elevation — a recognized class effect of GLP-1 receptor agonism — occurred in both arms. Neither agent showed a clinically meaningful between-group difference in heart rate change in SURMOUNT-5. Injection-site reactions were uncommon for both agents. The overall safety picture from SURMOUNT-5 supports the interpretation that tirzepatide's greater efficacy does not come at a cost of meaningfully worse tolerability in the trial population.
Cardiovascular Outcomes: A Consequential Evidence Asymmetry
Semaglutide 2.4 mg has a completed dedicated cardiovascular outcomes trial in the obesity-without-T2D population. Tirzepatide does not. This asymmetry is the single most clinically significant differentiator for specific patient profiles.
The SELECT trial (NCT03574597), published in NEJM 2023 (Lincoff et al.; PMID: 37952131), enrolled 17,604 adults aged ≥45 years with pre-existing atherosclerotic cardiovascular disease, BMI ≥27 kg/m², and no type 2 diabetes at enrollment. Participants received semaglutide 2.4 mg or placebo weekly. Over a median follow-up of approximately 40 months, the primary composite endpoint — MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) — was reduced by 20% with semaglutide versus placebo (HR 0.80; 95% CI: 0.72–0.90; p<0.001). This is prospective, randomized, adequately powered evidence of cardiovascular risk reduction with semaglutide 2.4 mg in the specific population of adults with established CVD and obesity but no T2D.
Tirzepatide's available CVOT data comes from SURPASS-CVOT (NCT04255433), which studied a type 2 diabetes population comparing tirzepatide to dulaglutide, demonstrating non-inferiority on MACE. SURMOUNT-MMO (NCT05556512) — the dedicated cardiovascular outcomes trial for tirzepatide in obesity without T2D — is enrolling; primary MACE results are not yet available. Until SURMOUNT-MMO reports, clinicians cannot draw on equivalent prospective CVOT data for tirzepatide in this patient subgroup.
For clinical decision-making: in an adult with established atherosclerotic cardiovascular disease and obesity but no type 2 diabetes, semaglutide 2.4 mg is the only agent with prospective, randomized evidence of MACE reduction at the approved obesity dose. Tirzepatide's superior weight-loss efficacy does not offset this evidence gap for cardiovascular risk management until SURMOUNT-MMO results become available.
Interpreting the Evidence: A Clinical Decision Framework
The SURMOUNT-5 result confirms that the weight-loss differential observed when comparing the separate STEP and SURMOUNT pivotal programs is a real pharmacological phenomenon, not an artifact of differing trial designs. The 6.5-percentage-point treatment difference is statistically robust and clinically meaningful — particularly for patients where deeper absolute weight reduction maps onto resolution of specific comorbidities such as obstructive sleep apnea, hepatic steatosis grade, or mechanical joint loading.
Patient profiles where tirzepatide's efficacy advantage is most directly supported by SURMOUNT-5:
- Adults with obesity requiring ≥20% weight reduction to meet individualized metabolic or structural targets
- Patients where ≥25% weight loss may alter the bariatric surgical risk-benefit calculation
- Patients without established CVD where the SELECT evidence base is not the primary prescribing consideration
Patient profiles where the semaglutide evidence base may be more directly applicable:
- Adults with established atherosclerotic cardiovascular disease and obesity without T2D, where SELECT provides the only prospective MACE-reduction data at the approved obesity dose
- Patients already achieving meaningful — though sub-target — weight reduction on semaglutide, where the transition carries clinical inertia risks without guaranteed net benefit for that individual
- Access-constrained cases: formulary positioning, prior authorization pathways, and patient assistance eligibility differ by payer and may not map onto clinical preference hierarchies
Cost and access remain practical constraints independent of efficacy. List prices for both agents exceed $1,000 per month in the United States as of mid-2025. FDA approval status: semaglutide 2.4 mg (Wegovy) received its obesity indication in June 2021; tirzepatide 2.5–15 mg (Zepbound) received its obesity indication in November 2023. Payer coverage under ICD-10 code E66.xx varies substantially by plan, formulary year, and state mandate status — factors that often determine real-world agent selection independent of clinical trial outcomes.
The outstanding question for tirzepatide in obesity is cardiovascular, not metabolic. SURMOUNT-5 has settled the efficacy question at the population level. SURMOUNT-MMO will determine whether the greater weight-loss magnitude with tirzepatide translates to equivalent or superior MACE reduction relative to the SELECT benchmark — and whether the CVOT evidence asymmetry that currently exists between these agents closes.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.